Legend Biotech's LB2501 Achieves 100% ORR, 83% CR in Phase 1 Lymphoma Study, Establishing Clinical Proof-of-Concept
LEGN has more than doubled off its 52-week low of $16.24.
Summary
Legend Biotech announced compelling clinical proof-of-concept data for its investigational LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma. At the higher dose level, LB2501 achieved a 100% objective response rate (ORR) and an 83.3% complete response (CR) in six patients. This follows earlier reports of strong preliminary Phase 1 data for LB2501 on June 2nd, now providing specific, highly positive efficacy numbers and a formal proof-of-concept. The therapy also demonstrated a favorable safety profile with no lymphodepletion required, a significant advantage for in vivo CAR-T. These results are exceptionally strong for an early-stage study in a difficult-to-treat patient population, significantly de-risking the program and highlighting LB2501's potential as a first-in-class therapy. The ability to generate CAR-T cells in vivo without lymphodepletion could simplify treatment and expand patient access.
At the time of this announcement, LEGN was trading at $35.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $16.24 to $45.30. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.